clobazam

clobazam
Drug name	Clobazam
Tradenames	Frisium, Onfi
Routes of administration	Oral, rectal
Class	1,5-benzodiazepine
Legal status	Varies by country
Metabolism	Hepatic (CYP3A4, CYP2C19)
Elimination half-life	18–50 hours

clobazam Clobazam is a 1,5-benzodiazepine used as an anticonvulsant and anxiolytic in selected United Kingdom, United States, and France clinical settings. It is prescribed for adjunctive therapy in refractory epilepsy syndromes such as Lennox–Gastaut syndrome and for short-term management of severe anxiety in some jurisdictions. Regulatory and clinical acceptance has involved agencies and organizations including the European Medicines Agency, the Food and Drug Administration, and national health services such as the National Health Service (England).

Medical uses

Clobazam is indicated as adjunctive treatment for seizures in Lennox–Gastaut syndrome and other refractory epilepsies with evidence from randomized trials and observational studies involving centers like Mayo Clinic, Johns Hopkins Hospital, and Great Ormond Street Hospital. It has been used off-label for anxiety disorders in clinical practice informed by guidelines from bodies such as the World Health Organization and the Royal College of Psychiatrists, and in acute management protocols within emergency departments at institutions like Massachusetts General Hospital and Karolinska University Hospital. Use in pediatric populations has been evaluated in multicenter studies conducted by networks including the International League Against Epilepsy and university hospitals like Boston Children's Hospital and SickKids Hospital.

Pharmacology

Clobazam acts as a positive allosteric modulator at the benzodiazepine site of GABAA receptor complexes, enhancing inhibitory neurotransmission in neuronal circuits investigated by research groups at Stanford University, Harvard Medical School, and the Max Planck Institute for Brain Research. Its active metabolite, desmethylclobazam, is formed via hepatic enzymes including CYP3A4 and CYP2C19, pathways characterized in pharmacokinetic studies by teams at University of Oxford and University of California, San Francisco. Plasma concentration–effect relationships and half-life determinations have been described in trials registered with regulators such as the European Medicines Agency and data collected in pharmacology units at Karolinska Institutet.

Contraindications and precautions

Contraindications include acute narrow-angle glaucoma and severe respiratory insufficiency as noted in product monographs approved by agencies like the Food and Drug Administration and the European Medicines Agency. Caution is advised in patients with a history of substance use disorders evaluated in cohorts from centers such as National Institute on Drug Abuse and Addiction Research Center, and in elderly patients monitored in geriatric clinics at Mayo Clinic and UCL Hospitals. Genetic polymorphisms in CYP2C19 affecting metabolism have prompted pharmacogenetic screening discussions in publications from institutions including University of Cambridge and Erasmus University Medical Center.

Adverse effects

Common adverse effects include sedation, ataxia, and cognitive impairment reported in clinical trials conducted at Vanderbilt University Medical Center and surveillance programs coordinated by the World Health Organization. Serious but less frequent events such as paradoxical reactions, dependence, and withdrawal seizures have been documented in case series from hospitals including Bellevue Hospital and university research groups at University of Sydney. Reporting systems such as the United States Drug Enforcement Administration databases and pharmacovigilance networks at the European Medicines Agency maintain records of adverse event profiles.

Interactions

Clobazam interacts with other central nervous system depressants including barbiturates and opioids as studied in toxicology units at Johns Hopkins Hospital and emergency medicine departments at Royal Infirmary of Edinburgh. Enzyme inhibitors and inducers of CYP3A4 and CYP2C19 — for example drugs reviewed by formularies at National Institute for Health and Care Excellence and the World Health Organization — alter clobazam and desmethylclobazam levels; concomitant use with agents such as fluvoxamine, ketoconazole, or rifampicin has been specifically characterised in drug interaction studies at University of Toronto and Imperial College London.

Chemistry and formulation

Clobazam is a 1,5-benzodiazepine with a chemical structure related to other benzodiazepines described in chemical literature from the American Chemical Society and the Royal Society of Chemistry. It is formulated for oral tablets and liquid suspensions marketed under trade names by pharmaceutical companies such as Eisai, and rectal formulations and compounded preparations have been used in acute seizure protocols in hospitals including St. Thomas' Hospital and Children's Hospital of Philadelphia. Analytical methods for assay and stability have been published by laboratories at European Pharmacopoeia-affiliated centers and industrial research units at multinational firms like GlaxoSmithKline.

History and legal status

Clobazam was developed in the 1960s and introduced into clinical practice in countries such as France and Belgium with historical accounts documented in pharmaceutical histories compiled by institutions like the Wellcome Trust. Its regulatory approvals and scheduling have varied: national agencies including the Food and Drug Administration, the European Medicines Agency, and the Therapeutic Goods Administration have issued labels and risk communications shaping clinical use in regions such as North America, Europe, and Australia. Patent and marketing histories involve manufacturers and legal proceedings referenced in archives of companies such as Eisai and regulatory case files at the European Court of Justice.

Category:Anticonvulsants